We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $82.24 · 21 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? The Motley Fool
Koss Olinger Consulting LLC Sells 30,750 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Koss Olinger Consulting LLC Sells 30,750 Shares of CRISPR Therapeutics AG $CRSP MarketBeat
Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026? - Yahoo Finance
Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026? Yahoo Finance
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Momentum And Gene Editing Pipeline Progress - simplywall.st
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Momentum And Gene Editing Pipeline Progress simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 11. | After market close (AMC) | $-1.18 | — | — | $6.42M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.58 | — | — | $865K | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-3.92 | — | — | $1.62M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-2.92 | — | — | $1.02M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Bernstein | — | Maintain | Market Perform → Market Perform | — | Bernstein: Market Perform |
| 2026. 05. 07. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 03. 17. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 02. 17. | Chardan Capital | — | Maintain | Buy → Buy | — | Chardan Capital: Buy |
| 2026. 02. 14. | TD Cowen | — | Maintain | Hold → Hold | — | TD Cowen: Hold |
| 2026. 02. 14. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,483,051 | $70.55B | 0.06% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 470,621 | $24.68B | 0.04% | — | New position |